Multidimensional Evaluation of Social Value of Pharmaceuticals
Yosuke Nakano (Senior Researcher, Pharmaceutical and Industrial Policy Research Institute)
Mariko Hirozane (Researcher, Graduate School of Pharmaceutical Sciences, The University of Tokyo)
Naka Igarashi (Associate Professor, Health and Social Medicine Unit, Yokohama City University School of Medicine, Visiting Associate Professor, Department of Pharmaceutical Policy Studies, Graduate School of Pharmaceutical Sciences, The University of Tokyo)
(No.76: Published in March 2021)
In order to evaluate the various values of pharmaceuticals, it is desirable to discuss and examine values from more diverse perspectives, such as social aspects, in addition to the perspective of cost-effectiveness.
Therefore, in this report, we focus on social value elements among the various values, and investigate the current status of outcome indicators and measurement of these elements, as well as the current status of evaluation overseas (mainly in the U.K.), with a view to considering and evaluating the various values of pharmaceutical products in the near future.
The social value elements in this study are based on the 9 elements from a social perspective among the 12 value elements proposed in the ISPOR report, and based on the evaluation cases of NICE in the U.K. and the trends of evaluation organizations in the U.K. and Canada triggered by the new coronavirus infection, we investigated "reduction of care burden (mainly for family members and caregivers)," "reduction of medical burden (mainly for caregivers)," and "reduction of medical burden for patients (mainly for caregivers). Based on the UK NICE evaluation case study and the trends of the UK and Canadian evaluation organizations in the wake of the novel coronavirus infection, we considered "reduction of caregiver burden (mainly for family members)" and "reduction of medical burden (human and material)" to be important factors, and decided to include these two factors in the study (see figure below).
In addition, examples of value presentation or evaluation utilizing outcome measurement results, etc. that could be confirmed in this study are also presented, divided into cases that can be considered quantitatively and those that can be considered qualitatively.
